Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors

NCT06382948 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT06382948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06382948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors
Lead sponsor
MedSIR
Phase
Phase 3
Overall status
Recruiting
Start date
December 5, 2024
Completion date
April 30, 2028
Enrollment
300 (estimated)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, er-positive breast cancer, esr1 gene mutation, her2-negative breast cancer